**Supplementary Table 2. Sensitivity analysis for the impact on OCT on tumor characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **No OCT**  **n=450**  **(%)** | **OCT total n=103**  **(%)** | **OCT only1**  **n=67**  **(%)** |  |
| 88 (20)  258 (57)  104 (23) | 31 (30)  45 (44)  27 (26) | 21 (31)  25 (38)  21 (31) | **T≤1 cm**  **1<T≤2**  **T>2 cm** |
| 79 (18) | 16 (16) | 10 (15) | **Node positive** |
| 354 (79)  62 (14)  34 (7) | 89 (86)  9 (9)  5 (5) | 56 (84)  7 (10)  4 (6) | **IDC**  **ILC**  **Other** |
| 64 (18)  231 (63)  70 (19) | 16 (18)  66 (72)  9 (10) | 12 (21)  41 (72)  4 (7) | **Grade**  **1**  **2**  **3** |
| 8 (2)  97 (21)  345 (77) | 3 (3)  23 (22)  77 (75) | 3 (5)  15 (22)  49 (73) | **ER intensity**  **Weak**  **Moderate**  **Strong** |
| 64 (14) | 8 (8) | 5 (8) | **PR Negative** |
| 22 (5) | 2 (2) | 2 (3) | **PNI present** |
| 21 (5) | 21 (5) | 8 (12) | **LVI present** |
| 72 (16) | 13 (18) | 5 (8) | **Ki67 >20%** |
| 83 (18) | 16 (16) | 9 (13) | **Oncotype RS>25** |

1 OCT only- included women who used OCT and were not treated with hormonal replacement therapy or fertility treatment

Abbreviation: OCT= Oral contraceptive therapy, , T=Tumor size, IDC= Invasive ductal carcinoma, ILC= Invasive lobular carcinoma, ER=Estrogen receptor, PR= Progesterone receptor, PNI= Perineural invasion, LVI= Lymphovascular invasion, RS= Recurrence score.